RSP AminoLean x Chase Byrd Cherry On Top is a multi-blend supplement categorized as a protein, though it primarily focuses on amino acids, weight management, and energy. A 9.6-gram serving contains 5 ingredients, including an Amino Acid Blend (5 grams), a Weight Management Blend (1.5 grams), and an Energy and Focus Blend (130mg). The product received an N+ Score of 48, earning an 'F' grade, indicating a below-average quality assessment. The use of proprietary blends for the amino acids, weight management, and energy components limits transparency regarding individual ingredient dosages, making it difficult to assess their efficacy. Phosphorus is also noted as underdosed at 80mg. This product may be considered by individuals seeking a pre-workout or anytime amino acid blend with added energy components, but the lack of specific ingredient dosing is a notable limitation.
About This Product
AminoLean x Chase Byrd Cherry On Top by RSP is a protein supplement containing 5 active ingredients. It has earned an N+ Score of 48/100 (Grade F).
N+ Score Breakdown
Are key ingredients present at clinically effective doses based on research?
Does the product include all expected ingredients for its supplement category?
Are individual ingredient amounts clearly disclosed without proprietary blends?
Does the formula include a breadth of beneficial compounds from multiple pathways?
Strengths
- +Fully transparent label with individual ingredient amounts disclosed
- +Broad ingredient diversity exceeding category norms
Weaknesses
- −Several ingredients below clinically effective doses
- −Missing several expected ingredients for its category
Ingredient Analysis (5 ingredients)
| Ingredient | Amount | Dose Adequacy |
|---|---|---|
| Sodium | 120.000 mg | N/A |
| Phosphorus | 80.000 mg | Under |
| Weight Management Blend | 1.500 Gram(s) | N/A |
| Amino Acid Blend | 5.000 Gram(s) | N/A |
| Energy and Focus Blend | 130.000 mg | N/A |
Clinical ranges based on NIH ODS Fact Sheets and peer-reviewed research. Status indicates whether the amount meets evidence-based thresholds.
